Multiple Sclerosis (MS) is the most common debilitating disease in young adults worldwide. Diagnosed in over 2.3 million people, this neuro-immunological disease is most prevalent in Europe and North America, with over 120,000 diagnosed cases in Germany alone. Great strides have been made in developing medications that slow disease progression, however, the daily symptomatology of MS remains large ...